Immuneering Corp Files 2023 Annual Report on Form 10-K

Ticker: IMRX · Form: 10-K · Filed: Mar 1, 2024 · CIK: 1790340

Immuneering Corp 10-K Filing Summary
FieldDetail
CompanyImmuneering Corp (IMRX)
Form Type10-K
Filed DateMar 1, 2024
Risk Levelmedium
Pages15
Reading Time17 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: 10-K, Immuneering Corp, Financial Report, Pharmaceuticals, SEC Filing

TL;DR

<b>Immuneering Corp filed its 2023 10-K, detailing financial performance and corporate structure.</b>

AI Summary

Immuneering Corp (IMRX) filed a Annual Report (10-K) with the SEC on March 1, 2024. Immuneering Corp reported its fiscal year results for the period ending December 31, 2023. The company's business address is 245 Main Street, Second Floor, Cambridge, MA 02142. Immuneering Corp is incorporated in Delaware and operates within the Pharmaceutical Preparations industry. The filing includes financial data for the fiscal years 2023, 2022, and 2021. Key events include the IPO on August 3, 2021, and an underwriting offering on April 20, 2023.

Why It Matters

For investors and stakeholders tracking Immuneering Corp, this filing contains several important signals. This 10-K filing provides a comprehensive overview of Immuneering Corp's financial health and operational status for the fiscal year 2023, crucial for investors assessing the company's trajectory. The detailed financial statements and risk factors within this report are essential for understanding the company's market position, potential challenges, and future growth prospects in the pharmaceutical sector.

Risk Assessment

Risk Level: medium — Immuneering Corp shows moderate risk based on this filing. The company operates in the pharmaceutical preparations industry, which is subject to significant regulatory oversight, lengthy development cycles, and intense competition, posing inherent risks to revenue generation and profitability.

Analyst Insight

Investors should review the detailed financial statements and risk factors in the 10-K to assess Immuneering Corp's long-term viability and potential for growth in the competitive biopharmaceutical market.

Key Numbers

  • 2023-12-31 — Fiscal Year End (Reporting period)
  • 2024-03-01 — Filing Date (Date of submission)
  • 2021-08-03 — IPO Date (Initial Public Offering)
  • 2023-04-20 — Underwriting Offering Date (Secondary offering)

Key Players & Entities

  • Immuneering Corp (company) — Filer name
  • 245 Main Street, Second Floor, Cambridge, MA 02142 (company) — Business Address
  • DE (company) — State of Incorporation
  • 2834 (company) — Standard Industrial Classification
  • 001-40675 (company) — SEC File Number
  • 2023-12-31 (date) — Fiscal Year End
  • 2024-03-01 (date) — Filed as of Date
  • 2021-08-03 (date) — IPO Date

FAQ

When did Immuneering Corp file this 10-K?

Immuneering Corp filed this Annual Report (10-K) with the SEC on March 1, 2024.

What is a 10-K filing?

A 10-K is a comprehensive annual financial report required by the SEC, covering audited financials, business operations, risk factors, and management discussion. This particular 10-K was filed by Immuneering Corp (IMRX).

Where can I read the original 10-K filing from Immuneering Corp?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Immuneering Corp.

What are the key takeaways from Immuneering Corp's 10-K?

Immuneering Corp filed this 10-K on March 1, 2024. Key takeaways: Immuneering Corp reported its fiscal year results for the period ending December 31, 2023.. The company's business address is 245 Main Street, Second Floor, Cambridge, MA 02142.. Immuneering Corp is incorporated in Delaware and operates within the Pharmaceutical Preparations industry..

Is Immuneering Corp a risky investment based on this filing?

Based on this 10-K, Immuneering Corp presents a moderate-risk profile. The company operates in the pharmaceutical preparations industry, which is subject to significant regulatory oversight, lengthy development cycles, and intense competition, posing inherent risks to revenue generation and profitability.

What should investors do after reading Immuneering Corp's 10-K?

Investors should review the detailed financial statements and risk factors in the 10-K to assess Immuneering Corp's long-term viability and potential for growth in the competitive biopharmaceutical market. The overall sentiment from this filing is neutral.

Key Dates

  • 2023-12-31: Fiscal Year End — End of the reporting period for the 10-K.
  • 2024-03-01: Filing Date — Date the 10-K was officially filed with the SEC.
  • 2021-08-03: IPO Date — Date of the company's Initial Public Offering.
  • 2023-04-20: Underwriting Offering — Date of a significant underwriting offering.

Filing Stats: 4,360 words · 17 min read · ~15 pages · Grade level 17.9 · Accepted 2024-03-01 08:05:34

Key Financial Figures

  • $0.001 — stered Class A common Stock, par value $0.001 per share IMRX The Nasdaq Global Market

Filing Documents

Business

Business 7 Item 1A.

Risk Factors

Risk Factors 48 Item 1B. Unresolved Staff Comments 104 Item 1C. Cyber s ecurity 104 Item 2.

Properties

Properties 105 Item 3.

Legal Proceedings

Legal Proceedings 105 Item 4. Mine Safety Disclosures 105 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 106 Item 6. [Reserved] 106 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 106 Item 7A.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 117 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 118 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 141 Item 9A.

Controls and Procedures

Controls and Procedures 141 Item 9B. Other Information 141 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 141 PART III Item 10. Directors, Executive Officers and Corporate Governance 142 Item 11.

Executive Compensation

Executive Compensation 142 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 142 Item 13. Certain Relationships and Related Transactions, and Director Independence 142 Item 14. Principal Account ant Fees and Services 142 PART IV Item 15. Exhibit and Financial Statement Schedules 142 Item 16. Form 10-K Summary 144 2 Table of Contents

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K contains forward-looking statements including within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. All statements other than statements of historical fact contained in this Annual Report on Form 10-K, including without limitation statements regarding our plans to develop, manufacture and commercialize our product candidates (including whether as potential monotherapies or in combination with other therapeutic agents), the design, timing, disclosure of data, or outcome of our ongoing or planned preclinical studies or clinical trials involving IMM-1-104, IMM-6-415, any of our other pipeline product candidates and any future product candidates, the clinical utility of our product candidates when administered alone or in combination with other therapeutic agents, the filing with, and approval by, regulatory authorities of our product candidates, and the sufficiency of funds to operate the business of the Company, are forward-looking statements. The forward-looking statements in this Annual Report on Form 10-K are only predictions and are based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and r

Business

Item 1. Business We are a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients. We aim to achieve such universal RAS/RAF activity through deep cyclic inhibition of the MAPK pathway, impacting cancer cells while sparing healthy cells. Our inclusive approach differentiates us from narrowly targeted precision therapies, which are limited to patients with tumors harboring select mutations. We are currently evaluating our lead product candidates, IMM-1-104 and IMM-6-415, in Phase 1/2a clinical trials in patients with advanced solid tumors harboring RAS and RAS/RAF mutations, respectively. IMM-1-104 is being developed as a once-daily oral therapy that aims to achieve universal-RAS activity through deep cyclic inhibition of the MAPK pathway. By contrast, IMM-6-415 aims to achieve universal-RAS/RAF activity with an accelerated twice-daily oral dosing cadence, also through deep cyclic inhibition of the MAPK pathway. Deep cyclic inhibition is a novel mechanism that aims to deprive tumor cells of the sustained proliferative signaling required for rapid growth, while sparing healthy cells through a cadenced, normalized level of signaling. This mechanism was engineered using our proprietary informatics-based discovery platform. The development of our pipeline is translationally guided by our proprietary, human-aligned 3D tumor modeling platform that we combine with bioinformatics-driven patient profiling, which we believe has the potential to increase the probability of success in clinical development versus traditional drug development approaches. Our pipeline also includes Trifecta MEK, RAS modulators and other small molecule drug discovery programs. In September 2022, the FDA cleared our Investigational New Drug ("IND") application for IMM-1-104 and, i n November 2022, we commenced dosing in our Phase 1/2a clinical trial of IMM-1-104 for the potential treatment of advanced RAS mutant solid

View Full Filing

View this 10-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.